The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Aldosterone Is Positively Associated With Circulating FGF23 Levels in Chronic Kidney Disease Across Four Species, and May Drive FGF23 Secretion Directly
Open accessAbstract
Background: Chronic kidney disease (CKD) is accompanied by increases in circulating fibroblast growth factor 23 (FGF23) and aldosterone levels. Here, we tested the hypothesis that aldosterone may be one of the driving forces behind increased FGF23 secretion in CKD. Methods: Using data from a prospective study in humans, a retrospective study in dogs and cats, and an experimental study in 5/6-nephrectomized mice, we analyzed the relationship between circulating FGF23 and serum aldosterone levels in CKD across four species. To assess the effects of acute inhibition of aldosterone signaling on circulating FGF23, we acutely treated mice with established CKD with the mineralocorticoid receptor blocker canrenone (50 mg/kg iv/sc), and measured intact FGF23 before and 24 h as well as 72 h after start of administration of the drug. Results: We found a tight positive association between circulating intact FGF23 and serum aldosterone in human, canine, and feline CKD patients, as well as in experimental murine CKD (humans: rS = 0.57, p = 0.0368; dogs: rS = 0.66, p = 0.0019; cats: rS = 0.75, p = 0.0003; mice: rS = 0.49, p = 0.0004). Injection of canrenone in mice with established CKD did not lead to changes in FGF23 levels within 24 h, but reduced FGF23 in all mice at 72 h. Conclusion: Aldosterone may drive enhanced FGF23 secretion in CKD, possibly explaining the tight positive association between circulating intact FGF23 and aldosterone in human, canine, and feline CKD patients as well as in experimental CKD models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Dopamine and aldosterone have been linked to phosphate homeostasis.
“Last we measured also other hormones that have been linked to phosphate homeostasis such as dopamine and aldosterone [3, 10, 12, 13, 24, 47, 57, 61, 62].”
From Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels (2025) · cites this paper as [47]
The Introduction links aldosterone to FGF23 secretion, and the Conclusion reports a positive association between aldosterone and circulating FGF23 in CKD. That supports the aldosterone part of the phosphate-homeostasis claim. The paper does not address dopamine, so it does not support that part of the sentence. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Klotho converts canonical FGF receptor into a specific receptor for FGF23
Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., & Yamashita, T. (2006) · Nature · doi:10.1038/nature05315 · Cited by 1,865
1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system
Li, Y. C., Kong, J., Wei, M., Chen, Z.-F., Liu, S. Q., & Cao, L.-P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215219 · Cited by 1,625
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.101545198 · Cited by 1,391
Isakova, T. (2011) · JAMA · doi:10.1001/jama.2011.826 · Cited by 1,023
Gutiérrez, O. M., Isakova, T., Rhee, E. P., Shah, A., Holmes, J., Collerone, G., Diaeresis]ppner, H. J., & Wolf, M. S. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010052 · Cited by 920
α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling
Chen, G., Yang, L., Goetz, R. M., Fu, L., Jayaraman, S., Hu, M. C., Moe, O. W., Liang, G., Li, X., & Mohammadi, M. (2018) · Nature · doi:10.1038/nature25451 · Cited by 501
Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production
David, V., Martin, A., Isakova, T., Spaulding, C., Qi, L., Ramirez, V., Zumbrennen‐Bullough, K. B., Sun, C. C., Lin, H. Y.-F., Babitt, J. L., et al. (2015) · Kidney International · doi:10.1038/ki.2015.290 · Cited by 495
Role of aldosterone in the remnant kidney model in the rat.
Greene, E. L., Kren, S. M., & Hostetter, T. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118867 · Cited by 476
Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism
Shimada, T., Yamazaki, Y., Takahashi, M., Hasegawa, H., Urakawa, I., Oshima, T., Ono, K., Kakitani, M., Tomizuka, K., Fujita, T., et al. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00474.2004 · Cited by 359
Acute and chronic regulation of aldosterone production
Hattangady, N. G., Olala, L. O., Bollag, W. B., & Rainey, W. E. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.034 · Cited by 347
Vitamin D Is a Regulator of Endothelial Nitric Oxide Synthase and Arterial Stiffness in Mice
Andrukhova, O., Slavić, S., Zeitz, U., Riesen, S. C., Heppelmann, M. S., Ambrisko, T. D., Markovic, M., Kuebler, W. M., & Erben, R. G. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1252 · Cited by 279
Self-citationIn Vivo klotho Gene Transfer Ameliorates Angiotensin II-Induced Renal Damage
Mitani, H., Ishizaka, N., Aizawa, T., Ohno, M., Usui, S.-I., Suzuki, T., Amaki, T., Mori, I., Nakamura, Y., Sato, M., et al. (2002) · Hypertension · doi:10.1161/01.hyp.0000013734.33441.ea · Cited by 256
Nagase, M., Shibata, S., Yoshida, S., Nagase, T., Gotoda, T., & Fujita, T. (2006) · Hypertension · doi:10.1161/01.hyp.0000222003.28517.99 · Cited by 248
Schjoedt, K. J., Andersen, S., Rossing, P. R., Tarnow, L., & Parving, H. (2004) · Diabetologia · doi:10.1007/s00125-004-1542-0 · Cited by 246
Andrukhova, O., Zeitz, U., Goetz, R. M., Mohammadi, M., Lanske, B., & Erben, R. G. (2012) · Bone · doi:10.1016/j.bone.2012.05.015 · Cited by 228
Self-citationMacFadyen, R. J., Lee, A. F. C., Morton, J. J., Pringle, S. D., & Struthers, A. D. (1999) · Heart · doi:10.1136/hrt.82.1.57 · Cited by 205
Shimamura, Y., Hamada, K., Inoue, K., Ogata, K., Ishihara, M., Kagawa, T., Inoue, M., Fujimoto, S., Ikebe, M., Yuasa, K., et al. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0621-7 · Cited by 184
Aldosterone in Chronic Kidney and Cardiac Disease
Hostetter, T. H., & Ibrahim, H. N. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000086472.65806.73 · Cited by 137
Update on FGF23 and Klotho signaling
Erben, R. G. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.05.008 · Cited by 119
Self-citationFGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis
Böckmann, I., Lischka, J., Richter, B., Deppe, J., Rahn, A., Fischer, D., Heineke, J., Haffner, D., & Leifheit‐Nestler, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184634 · Cited by 106
Leifheit‐Nestler, M., Kirchhoff, F., Nespor, J., Richter, B., Soetje, B., Klintschar, M., Heineke, J., & Haffner, D. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy006 · Cited by 105
Fibroblast Growth Factor 23 in Feline Chronic Kidney Disease
Geddes, R. F., Finch, N., Elliott, J., & Syme, H. M. (2013) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.12044 · Cited by 99
Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor
Zanchi, C., Locatelli, M., Benigni, A., Corna, D., Tomasoni, S., Rottoli, D., Gaspari, F., Remuzzi, G., & Zoja, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070775 · Cited by 98
Up-regulation of FGF23 release by aldosterone
Zhang, B., Umbach, A. T., Chen, H., Yan, J., Fakhri, H., Fajol, A., Salker, M. S., Spichtig, D., Daryadel, A., Wagner, C. A., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.034 · Cited by 91
High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease
Lau, W. L., Linnes, M. P., Chu, E. Y., Foster, B. L., Bartley, B., Somerman, M. J., & Giachelli, C. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs333 · Cited by 72
Key role of the kidney in the regulation of fibroblast growth factor 23
Mace, M. L., Gravesen, E., Hofman-Bang, J., Ølgaard, K., & Lewin, E. (2015) · Kidney International · doi:10.1038/ki.2015.231 · Cited by 69
Geddes, R. F., Elliott, J., & Syme, H. M. (2015) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.13625 · Cited by 69
Kovesdy, C. P., & Quarles, L. D. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00606.2015 · Cited by 65
Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
Yang, J., & Young, M. J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.005 · Cited by 64
Erben, R. G. (2017) · Toxicologic Pathology · doi:10.1177/0192623317737469 · Cited by 53
Self-citationFibroblast Growth Factor-23 Concentration in Dogs with Chronic Kidney Disease
Harjes, L. M., Parker, V. J., Dembek, K. A., Young, G. S., Giovaninni, L. H., Kogika, M. M., Chew, D. J., & Toribio, R. E. (2017) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.14707 · Cited by 40
Andrukhova, O., Schüler, C., Bergow, C., Petric, A., & Erben, R. G. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00311 · Cited by 26
Self-citationXu, H., Hashem, A., Witasp, A., Mencke, R., Goldsmith, D. J. A., Barany, P. F., Bruchfeld, A. N., Wernerson, A. M., Carrero, J. J., & Olauson, H. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy315 · Cited by 17
Kim, H., Lee, M., Jo, S., Seo, W., Kim, S. E., Kim, K.-J., Choi, J., Ahn, H., Choi, D., & Ryu, K.-H. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0782 · Cited by 13
Dual RAAS blocker trial stopped prematurely
Cully, M. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.169 · Cited by 3
Dual RAAS blocker trial stopped prematurely
Cully, M. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.254 · Cited by 3
Flagged first, then by citations
Cited by
Sorted by citations
Epstein, M., Kovesdy, C. P., Clase, C. M., Sood, M. M., & Pecoits‐Filho, R. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.04.016 · Cited by 121
New concepts in regulation and function of the FGF23
Dastghaib, S., Koohpeyma, F., Shams, M., Saki, F., & Alizadeh, A. A. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00844-x · Cited by 21
Epstein, M. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.008 · Cited by 20
Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels
Gerber, J. S., Arroyo, E. M. P., Pastor, J., Correia, M., Rudloff, S., Moe, O. W., Egli-Spichtig, D., Mohebbi, N., & Wagner, C. A. (2025) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03046-4 · Cited by 15
Park, M. Y., Tu, C., Pèrié, L., Verma, N., Serdan, T. D. A., Shamsi, F., Shapses, S. A., Heffron, S. P., Gamallo‐Lana, B., Mar, A. C., et al. (2024) · Endocrinology · doi:10.1210/endocr/bqae141 · Cited by 9
Dörr, K., Kammer, M., Reindl‐Schwaighofer, R., Lorenz, M., Marculescu, R., Poglitsch, M., Beitzke, D., & Oberbauer, R. W. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.878730 · Cited by 8
Self-citationHypertension in Cardiovascular and Kidney Disease: Recent Trends – Treating Two Diseases as One
Pascalis, A. D., Tomassetti, A., Vetrano, D., Tringali, E., Lullo, L. D., Napoli, M., Manna, G. L., & Cianciolo, G. (2024) · Cardiorenal Medicine · doi:10.1159/000541876 · Cited by 7
Summers, S., Michael, H. T., Szlosek, D. A., & Mack, R. (2024) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x241234984 · Cited by 7
Okamoto, K., Fujii, H., Watanabe, K., Goto, S., Kono, K., & Nishi, S. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab187 · Cited by 7
Castoldi, G., Carletti, R., Ippolito, S., Villa, I., Palmisano, B., Bolamperti, S., Rubinacci, A., Zerbini, G., Meani, M., Zatti, G., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10112928 · Cited by 6
Dohuim, A. H. E., Ghazy, M., Nosair, N. A. E.-A., & Hussien, A. K. (2025) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-025-00435-8 · Cited by 4
Elliott, J., & Tang, P. K. (2024) · The Veterinary Journal · doi:10.1016/j.tvjl.2024.106271 · Cited by 3
Kim, M., Lee, H. Y., & Kim, H. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.160 · Cited by 3
Vetrano, D., Pascalis, A. D., Tomassetti, A., Comai, G., Nunzio, M. D., Barbuto, S., Sinagra, G., Manna, G. L., & Cianciolo, G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106987 · Cited by 3
Riz, F. D., Pichard, D., Maurey, C., Kurtz, M., Canonne‐Guibert, M., Lavoué, R., Trumel, C., Buronfosse, T., Desquilbet, L., & Benchekroun, G. (2024) · The Veterinary Journal · doi:10.1016/j.tvjl.2024.106146 · Cited by 3
Urinary tetrahydroaldosterone is associated with circulating FGF23 in kidney stone formers
Moor, M. B., Dhayat, N. A., Schietzel, S., Größl, M., Vogt, B., & Fuster, D. G. (2022) · Urolithiasis · doi:10.1007/s00240-022-01317-2 · Cited by 3
Marques, P. L., Galac, S., Mateus, L. M., & Leal, R. O. (2025) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2025.106955 · Cited by 1
Wang, X., Li, J., Wang, X., Zhu, X., Liu, C., Zhao, N., Sun, D., Yuan, J., & Ma, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1799186 · Cited by 1
Wu, V., Peng, K., Chen, T.-I., Sun, C.-Y., Liao, H., Chan, C., Lin, Y., Liou, H., & Chueh, S. (2025) · JCI Insight · doi:10.1172/jci.insight.166461 · Cited by 1
Endocrine fibroblast growth factors in domestic animals
Brinker, E. J., Hardcastle, M., Dittmer, K. E., & Graff, E. C. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106872
Feliner Hyperaldosteronismus in Frage und Antwort
von Luckner, J., & Sieber‐Ruckstuhl, N. S. (2026) · Tierärztliche Praxis Ausgabe K Kleintiere / Heimtiere · doi:10.1055/a-2787-1734
Hu, J., Pan, X., Wei, S., & Wei, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1938521
Serum fibroblast growth factor-23 concentration in dogs with myxomatous mitral valve disease
Iwasa, N., Shimizu, M., Okamoto, T., kosuga, H., Morikita, N., Kawabe, M., Iwata, M., Watanabe, K., Kobatake, Y., Takashima, S., et al. (2026) · Journal of Veterinary Internal Medicine · doi:10.1093/jvimsj/aalag265
Metadata
- Authors
- Radloff, J., Pagitz, M., Andrukhova, O., Oberbauer, R., Burgener, I. A., & Erben, R. G.
- Affiliations
- University of Veterinary Medicine Vienna (AT)
- Medical University of Vienna (AT)
- Corresponding author
- Erben, Reinhold G.
- Venue
- Frontiers in Physiology
- Publisher
- Frontiers Media SA
- Published
- 2021-04-29
- Volume
- 12
- Pages
- 649921-649921
- ISSN
- 1664-042X (ISSN-L)
- PMC
- PMC8117232
- OpenAlex
- W3159120427
- Cited by
- 23
- References
- 38
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 7 · 2022: 6 · 2021: 1
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Physiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Austrian Science Fund (P24186-B21)
- Topics
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- aldosterone, fibroblast growth factor 23, chronic kidney disease, mineralocorticoid receptor, canrenone, cross-species comparison, dogs, cats, 5/6 nephrectomy, mineral metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
